ERRATA

ERRATA
‘‘EFFECTS OF CICLESONIDE AND FLUTICASONE ON CORTISOL SECRETION IN PATIENTS WITH PERSISTENT
ASTHMA’’. E. DEROM, R. LOUIS, C. TIESLER, R. ENGELSTÄTTER, J-M. KAUFMAN AND G.F. JOOS. EUR RESPIR J
2009; 33: 1277–1286.
Regrettably, the information regarding ciclesonide and fluticasone propionate was presented incorrectly in figure 1 of the above
paper. Throughout the figure, ‘‘mg?mL-1’’ should have appeared as ‘‘mg?day-1’’. In addition, figure 5 of the above paper appeared
with an incorrect axis label. ‘‘PC20 methacholine mg?mL-1’’ on the y-axis of the figure, should have appeared as ‘‘PC20 adenosine
mg?mL-1’’. The correct figures appear below:
Run-in
period
(4–6 weeks)
Treatment
period I
(9 days)
Washout
period I
(4–12 weeks)
Treatment
period II
(9 days)
Washout
period II
(4–12 weeks)
CIC 320 µg·day-1
FP 1000 µg·day-1
CIC 640 µg·day-1
FP 500 µg·day-1
FP 500 µg·day-1
Placebo
FP 1000 µg·day-1
CIC 320 µg·day-1
Treatment and
washout
periods
III–V
(9 days)
Follow-up
CIC 640 µg·day-1
Placebo
B0
FIGURE 1.
T1
T0
T2
T3
T4 T5
T8 – T14/Tend
Study design. Visits T0–T1, T3–T4, T6–T7, T9–T10 and T12–T13 were separated by 7¡0 days. Visits T0–T2, T3–T5, T6–T8, T9–T11 and T12–T14 were separated by
9 (-2/+3) days. CIC: ciclesonide; FP: fluticasone propionate; T: treatment visit.
256
PC20 adenosine mg·mL-1
164.6
128
179.6
139.7
103.3
64
51.3
32
16.7
16
8
Base
FIGURE 5.
PLA
CIC320
CIC640
FP500
FP1000
Provocative concentration leading to a 20% decrease in forced expiratory volume in 1 s (PC20) adenosine at intake (base) and after placebo (PLA),
ciclesonide (CIC) and fluticasone (FP). All treatment groups were administered CIC 160 mg once daily in the evening plus salmeterol 50 mg twice daily. CIC320: CIC
320 mg?day-1; CIC640: CIC 640 mg?day-1; FP500: 500 mg?day-1; FP1000: FP 1,000 mg?day-1.
DOI: 10.1183/09031936.50079908
EUROPEAN RESPIRATORY JOURNAL
VOLUME 34 NUMBER 3
783